D'Souza Anita, Lee Stephanie, Zhu Xiaochun, Pasquini Marcelo
Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin; Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, Washington.
Biol Blood Marrow Transplant. 2017 Sep;23(9):1417-1421. doi: 10.1016/j.bbmt.2017.05.035. Epub 2017 Jun 9.
Hematopoietic Cell Transplantation (HCT) is an established curative treatment for a number of malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. In this report, we provide information about the number of HCT procedures performed in the United States in 2015, and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We show that the number of HCTs performed annually continues to increase, as the indications for HCT, preferred donor sources, and graft-versus-host prophylaxis continue to evolve. We report on general overall survival by indication, by disease status at transplantation, and by transplant type. This report provides a current perspective on transplantation activity in the United States with a focus on recent trends in alternative donors and contemporary transplantation practices.
造血细胞移植(HCT)是一种已确立的针对多种涉及造血系统的恶性和非恶性疾病以及一些实体瘤的治愈性治疗方法。在本报告中,我们提供了2015年美国进行的HCT手术数量的信息,并分析了向国际血液和骨髓移植研究中心(CIBMTR)报告的HCT的趋势和结果。我们表明,随着HCT的适应症、首选供体来源和移植物抗宿主病预防措施不断发展,每年进行的HCT数量持续增加。我们按适应症、移植时的疾病状态和移植类型报告总体生存率。本报告提供了美国移植活动的当前视角,重点关注替代供体的最新趋势和当代移植实践。